Visualization of tau oligomers in TauP301L‐BiFC transgenic mice exhibits the progression of tauopathy. (20th December 2022)

• Record Type: Journal Article
• Authors: Lim, Sungsu; Pae, Ae Nim; Kim, Yun Kyung
• Is Part Of: Alzheimer's & dementia. Volume 18(2022)Supplement 3
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-20
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.062847
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Accumulation of abnormal tau aggregates in the brain is a pathological hallmark of multiple neurodegenerative disorders including Alzheimer's disease (AD). Increasing evidence suggests that soluble tau aggregates play a key role in tau pathology as neurotoxic species causing neuronal cell death and act as prion‐like seeds mediating tau propagation. Despite the pathological relevance, there is a paucity of methods to monitor tau oligomerization in the brain. Therefore, we have developed a novel tau transgenic mouse model as a tool to monitor tau self‐assembly in the brain. Method: We introduced bimolecular fluorescence complementation (BiFC) technique to human tau containing a P301L mutation to generate a novel tau transgenic mouse, named TauP301L‐BiFC. Tau self‐assembly, represented by BiFC fluorescence was monitored and quantified in the brain of transgenic TauP301L‐BiFC mice. Behavior and biochemical differences were assessed between 3 and 12 months for the characterization of TauP301L‐BiFC mice. In vivo efficacy of methylene blue, a tau aggregation inhibitor, was evaluated for further validation of TauP301L‐BiFC mice as an in vivo model of tauopathy. Results: TauP301L‐BiFC mice showed soluble tau oligomerization from 3 months, showing significantly enriched BiFC fluorescence in the brain. Then, massive tau fragmentation occurred at 6 months showing dramatically decreased TauP301L‐BiFC fluorescence. The fragmented tau species served as a seed for insoluble tau aggregation. In a result, insoluble TauP301L‐BiFC aggregates co‐aggregated with endogenous mouse tau accumulated in the brain, showing subsequently increased BiFC fluorescence from 9 months. Neuronal degeneration and cognitive deficits were observed from 12 months of age. Administration of methylene blue significantly reduced tau‐BiFC fluorescence in the brain of TauP301L‐BiFC mice, presenting a significant decrease in the level of matured tau‐BiFC complexes in the soluble brain lysates. TauP301L‐BiFC mouse model demonstrated that methylene blue reduced the amount of soluble tau oligomers in the brain, resulting in the prevention of cognitive impairments. Conclusion: The tau oligomerization was able to monitor and quantify in the brain of TauP301L‐BiFC mice. Thus, we assure that TauP301L‐BiFC mice are a bonafide animal tool to monitor pathological tau oligomerization in AD and other tauopathies.